Health data tool AcuityMD closes $7M round; AI mental health chatbot Whysa scores $5.5M and other digital health fundings

Also: MindPortal lands $5 million for its wearable noninvasive brain-computer device and Docbot raises $4 million for its GI-disease-detecting software.
By Mallory Hackett
11:21 am

Photo: Kwanchai Lerttanapunyaporn/EyeEm/Getty Images

AcuityMD, the creator of a data platform for medical device companies, closed a $7 million funding round led by Benchmark, with participation from Ajax Health.

Benchmark General Partner Eric Vishria is joining AcuityMD’s board of directors as part of its investment.

The company launched in 2020 with the mission of breaking down data silos for medical device developers. The AcuityMD platform combines medical device data from sales to patient outcomes so that manufacturers can track the performance of their products.

“AcuityMD sits at the intersection of healthcare, R&D and data, and we couldn’t have better investors to help us tackle this opportunity,” Mike Monovoukas, CEO and cofounder of AcuityMD, said in a statement. “Benchmark has an unrivaled track record in building marketplaces and expansive enterprise networks, including in the health-tech sector, while Ajax brings deep expertise in the medical device industry.”

The funding will go towards hiring, as AcuityMD works to double its team this year. It will also invest in product development, according to the announcement.

Artificial intelligence-powered mental health platform Wysa raised $5.5 million in a Series A funding round led by W Health Ventures.

The Google Assistant Investment program and existing investors pi Ventures and Kae Capital also participated in the financing round.

Wysa’s platform deploys an AI chatbot that uses cognitive behavioral therapy techniques to help users with their stress, depression and anxiety. The company also has an offering for employers that maintains worker anonymity, but provides population data so that employers can track their employees’ wellbeing.

The funding will go towards scaling Wysa’s sales team and therapist network, as well as building out its employer offering.

MindPortal, a developer of a patent-pending wearable noninvasive brain-computer interface, completed a seed round worth $5 million, led by Learn Capital.

Other investors include Kleiner Perkins; Dan Siroker, founder and CEO of Scribe AI; Matt Bellamy, front man of Muse; James Park, cofounder and CEO of Fitbit; Julie Zhou, cofounder of Sundial; Scrum Ventures and additional angel investors.

MindPortal’s wearable device records brain activity in real time. Its not-yet-released platform will allow users to engage with immersive virtual reality experiences and create their own with their thoughts alone.

"All technology has been generated from the ingenuity of the human mind, but for the first time in the history of our species, we are turning that ingenuity towards creating technology that enhances the human mind itself," Ekram Alam, cofounder and CEO of MindPortal, said in a statement.

The company will use the capital to hire additional neuroscientists, product engineers and machine learning experts.

Docbot, an AI clinical decision support company focused on gastrointestinal disease, landed $4 million in Series A funding. In addition, the company appointed Andrew Ritter as its new CEO.

Ritter has over 16 years of experience in GI disease and earned an MBA from the Wharton School at the University of Pennsylvania. The company’s founding CEO, Andrew Ninh, has moved to the chief strategic officer position, where he will lead business development, strategic partnerships and innovation.

Docbot’s latest funding raise, led by Khosla Ventures and with participation from Bold Capital Partners, the Collaborative Fund and Boutique Venture Partners, brings its total funding to $8.5 million.

The company’s lead product, UltivisionAI, can be used in real time to help clinicians detect and diagnose GI disease. The new cash will go towards clinical trial development for UltivisionAI as the company seeks FDA clearance.

“We’re excited to partner with these top-tier investors,” Ritter said in a statement. “With new funding, we will expand our team and advance our technology platform, while growing clinical evidence for the value of UltivisionAI.”



The latest news in digital health delivered daily to your inbox.

Thank you for subscribing!
Error! Something went wrong!